Quince Therapeutics (QNCX) Non Operating Interest Expenses (2018)
Quince Therapeutics (QNCX) posted Non Operating Interest Expenses of $358000.0 for Q2 2018, down 40.23% on a QoQ basis from $599000.0 in Q1 2018.
Powered by 
Analysis
Quince Therapeutics (QNCX) Non Operating Interest Expenses (2018) Analysis & Trends
Quince Therapeutics has reported Non Operating Interest Expenses for 1 years, with the latest figure at $358000.0 in Q2 2018.
- On a quarterly basis, Non Operating Interest Expenses changed N/A year-over-year to $358000.0 in Q2 2018; TTM through Dec 2018 was $957000.0, a N/A change from a year earlier, with the FY2018 full-year figure at $957000.0, changed N/A from the prior year.
- Non Operating Interest Expenses was $358000.0 for Q2 2018 at Quince Therapeutics, down from $599000.0 in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $599000.0 in Q1 2018, with the low at $358000.0 in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Quince Therapeutics | 175.52 Mn | 175.52 Mn | - | - |